Matinas BioPharma (MTNB) 10-K 30 Mar 16 2015 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Mar. 01, 2016	Jun. 30, 2015
Document Information [Line Items]
Entity Registrant Name	Matinas BioPharma Holdings, Inc.
Entity Central Index Key	1,582,554
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2015
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 34.5
Document Fiscal Period Focus	FY
Trading Symbol	MTNB
Document Fiscal Year Focus	2,015
Entity Common Stock, Shares Outstanding		57,180,148

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Dec. 31, 2015	Dec. 31, 2014
CURRENT ASSETS
Cash	$ 3,226,997	$ 2,590,713
Restricted cash - current	100,326	100,000
Prepaid expenses	231,797	114,425
Total current assets	3,559,120	2,805,138
Equipment - net	377,723	339,995
In-process research and development	3,017,377	0
Goodwill	1,336,488	0
Other assets including long term security deposit	115,370	216,317
TOTAL ASSETS	8,406,078	3,361,450
CURRENT LIABILITIES
Accounts payable	497,842	271,155
Accrued expenses	610,206	802,746
Deferred rent liability	9,225	0
Lease liability	11,261	44,362
Total current liabilities	1,128,534	1,118,263
LONG TERM LIABILITIES
Deferred tax liability	1,205,141	0
Lease liability - long term	0	15,291
TOTAL LIABILITIES	$ 2,333,675	$ 1,133,554
Commitments and contingencies
STOCKHOLDERS' EQUITY
Common stock par value $ 0.0001, 250,000,000 and 150,000,000 shares authorized, at December 31, 2015 and 2014, respectively; 57,180,148 issued and outstanding as of December 31, 2015; 32,292,650 issued and outstanding as of December 31, 2014	$ 5,719	$ 3,230
Additional paid in capital	29,253,848	16,276,430
Accumulated deficit	(23,187,164)	(14,051,764)
Total stockholders' equity	6,072,403	2,227,896
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 8,406,078	$ 3,361,450

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets [Parenthetical] - $ / shares	Dec. 31, 2015	Dec. 31, 2014
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized	250,000,000	150,000,000
Common Stock, Shares, Issued	57,180,148	32,292,650
Common Stock, Shares, Outstanding	57,180,148	32,292,650

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Revenue:
Contract research revenue	$ 194,494	$ 0
Costs and Expenses:
Research and development	5,292,193	5,175,520
General and administrative	4,813,800	5,289,479
Total costs and expenses	10,105,993	10,464,999
Loss from operations	(9,911,499)	(10,464,999)
Sale of New Jersey net operating loss	756,472	269,127
Other income/(expense), net	19,627	(25,173)
Net loss	$ (9,135,400)	$ (10,221,045)
Net loss per share - basic and diluted (in dollars per share)	$ (0.18)	$ (0.32)
Weighted average common shares outstanding:
Basic and diluted (in shares)	51,481,002	32,076,717

STATEMENT OF STOCKHOLDERS' EQUI

STATEMENT OF STOCKHOLDERS' EQUITY - USD ($)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2013	$ 10,474,788	$ 3,200	$ 14,302,307	$ (3,830,719)
Balance (in shares) at Dec. 31, 2013		32,000,000
Stock Based Compensation	1,821,402	$ 0	1,821,402	0
Issuance of common stock for serivces	152,751	$ 30	152,721	0
Issuance of common stock for serivces (in shares)		292,650
Net loss	(10,221,045)	$ 0	0	(10,221,045)
Balance at Dec. 31, 2014	2,227,896	$ 3,230	16,276,430	(14,051,764)
Balance (in shares) at Dec. 31, 2014		32,292,650
Shares issued for Aquarius Inc. Purchase January 29, 2015	2,119,689	$ 460	2,119,229	0
Shares issued for Aquarius Inc. Purchase January 29, 2015 (in shares)		4,608,020
Aquarius Inc. Contingent Equity Consideration	753,346	$ 0	753,346	0
Stock Based Compensation	1,354,373	0	1,354,373	0
Private Placements	8,522,164	$ 2,001	8,520,163	0
Private Placements (in shares)		20,000,000
Private Placement Issuance Costs	(7,945)		(7,945)	0
Issuance of common stock as Compensation for services	237,995	$ 28	237,967	0
Issuance of common stock as Compensation for services (in shares)		278,784
Issuance of common stock for excercised options	285	$ 0	285	0
Issuance of common stock for excercised options (in shares)		694
Net loss	(9,135,400)	$ 0	0	(9,135,400)
Balance at Dec. 31, 2015	$ 6,072,403	$ 5,719	$ 29,253,848	$ (23,187,164)
Balance (in shares) at Dec. 31, 2015		57,180,148

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flow - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Cash flows from operating activities:
Net loss	$ (9,135,400)	$ (10,221,045)
Adjustments to reconcile net loss to net cash ( used in) operating activities:
Depreciation and amortization	43,502	41,581
Deferred rent	9,225	0
Share based compensation and other expense	1,592,367	1,974,153
Changes in operating assets and liabilities, net of amounts acquired:
Grant receivable	45,643	0
Prepaid expenses	(111,588)	(29,932)
Other assets	100,621	(539)
Accounts payable	(73,726)	(125,613)
Accrued expenses	(285,047)	400,199
Net cash used in operating activities	(7,814,403)	(7,961,196)
Cash flows from investing activities
Equipment purchases	(76,179)	(288,519)
Acquisition of Aquarius - cash acquired	70,754	0
Net cash used in investing activities	(5,425)	(288,519)
Cash flows from financing activities:
Issuance of common stock net of offering expense	8,514,504	0
Payments of - lease liability	(48,392)	0
Payment of - notes payable	(10,000)	0
Net cash provided by financing activities	8,456,112	0
Net increase (decrease) in cash and cash equivalents	636,284	(8,249,715)
Cash and cash equivalents at beginning of period	2,590,713	10,840,428
Cash and cash equivalents at end of period	3,226,997	2,590,713
Supplemental non-cash financing activities
Capital lease for equipment purchase	0	111,095
Contingent equity consideration for Aquarius merger	753,346	0
Stock consideration for Aquarius merger	$ 2,119,689	$ 0

Nature of Business

Nature of Business	12 Months Ended
	Dec. 31, 2015
Disclosure Of Company Information And History [Abstract]
Nature of Operations [Text Block]	[1] Corporate History Matinas BioPharma Holdings Inc. (“Holdings”) is a Delaware corporation formed in 2013. Holdings is the parent company of Matinas BioPharma, Inc. (“BioPharma”), and Aquarius Biotechnologies, Inc., its operating subsidiaries (“Aquarius”, and together with “Holdings” and “BioPharma”, “the Company” or “we” or “our” or “us”). The Company is a development stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. On July 11, 2013, and contemporaneously with the initial closing of a private placement in July and August 2013 described below, BioPharma entered into a merger agreement whereby it became a wholly owned subsidiary of Holdings (the “Merger”) to effect its recapitalization plan. In connection with the Merger, the stockholders of BioPharma became the stockholders of the Holdings and received an aggregate of 9,000,000 1,000,000 15,000,000 7,500,000 On January 29, 2015, we completed the acquisition of Aquarius (Aquarius Merger), a New Jersey-based, early-stage pharmaceutical company focused on the development of differentiated and orally delivered therapeutics based on a proprietary, lipid-based, drug delivery platform called “cochleate delivery technology.” Following the Aquarius Merger, we are a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective broad spectrum antifungal and anti-bacterial therapeutics for the treatment of serious and life-threatening infections, using our innovative lipid-crystal nano-encapsulation drug delivery platform. See Note D for additional information on this transaction. On April 10, 2015, we completed a private placement (“2015 Private Placement”), under which the Company sold an aggregate of 20,000,000 20,000,000 8.5 [2] Proprietary Products and Technology Portfolios Our proprietary cochleate lipid-crystal nano-particle delivery technology platform, licensed from Rutgers University on an exclusive worldwide basis, is designed specifically for the targeted and safe delivery of orally bioavailable pharmaceuticals directly to the site of infection or inflammation. This license comprises a range of issued patents and patent applications, as well as the use of proprietary know-how with respect to the manufacturing and testing of products using this technology. Our lead product candidate using the cochleate delivery technology is MAT2203, an oral formulation of the broad spectrum intravenous(IV)-delivered anti-fungal agent amphotericin B. MAT2203 is under development for serious fungal infections and a single-escalating-dose Phase 1 study with MAT2203 has been completed. The Company is developing MAT2203 in collaboration with the National Institute of Allergy and Infectious Diseases, or NIAID, of the National Institutes of Health, or NIH. The U.S. Food and Drug Administration (FDA) has designated MAT2203 as a Qualified Infectious Disease Product (QIDP) with Fast Track status for the treatment of aspergillus. We are developing a pipeline of targeted delivery formulations by applying our cochleate oral delivery technology to a potentially broad array of proven medications, including MAT2501. MAT2501 is an oral cochleate formulation of the broad spectrum intravenous (IV)-delivered aminoglycoside antibiotic called amikacin, which is most often used for treating severe, hospital-acquired infections, including Gram-negative bacterial infections. The Company has an open Investigational New Drug (IND) application for MAT2501. MAT2501, has been granted a QIDP designation and Orphan Drug designation by the U.S. FDA. In addition, the Company is exploring development and partnership options for MAT9001, prescription-only omega-3 fatty acid-based composition under development for hypertriglyceridemia.

Going Concern and Plan of Opera

Going Concern and Plan of Operations	12 Months Ended
	Dec. 31, 2015
Plan Of Operations and Going Concern [Abstract]
Plan Of Operations And Going Concern [Text Block]	NOTE B - Going Concern and Plan of Operation The accompanying financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern. The Company has experienced net losses and negative cash flows from operations each period since its inception. Through December 31, 2015, the Company had an accumulated deficit of approximately $ 23.2 9.1 10.2 The Company has been engaged in developing a pipeline of product candidates since 2011. To date, the Company has not obtained regulatory approval for any of its product candidates nor generated any revenue from products and the Company expects to incur significant expenses to complete development of its product candidates. The Company may never be able to obtain regulatory approval for the marketing of any of its product candidates in any indication in the United States or internationally and there can be no assurance that the Company will generate revenues or ever achieve profitability. Assuming the Company obtains FDA approval for one or more of its product candidates, which the Company does not expect to receive until 2020 at the earliest, the Company expects that its expenses will continue to increase once the Company reaches commercial launch. The Company also expects that its research and development expenses will continue to increase as it moves forward for other indications for its lead product candidates and diversifies its R&D portfolio. As a result, the Company expects to continue to incur substantial losses for the foreseeable future, and that these losses will be increasing. The Company will need to secure additional capital in order to fund operations and to continue and complete its planned clinical and operational activities related to the product candidates and technologies that the Company recently acquired from Aquarius. The Company can provide no assurances that such additional financing will be available to the Company on acceptable terms, or at all. During the third quarter of 2015, the Company instituted cost deferral and savings measures to preserve its cash. The Company has taken steps to reduce and delay expenses through the timing and monitoring of our preclinical animal programs and as well as reducing professional fees, and compensation expenses in the short term. The Company is anticipating that the existing cash balance on hand at December 31, 2015 would be sufficient to meet its operating obligations through July 2016. The Company’s recurring losses from operations, and need for additional funding, raise substantial doubt about its ability to continue as a going concern, and as a result, the Company’s independent registered public accounting firm included an explanatory paragraph in this report on the Company’s financial statements as of and for the year ended December 31, 2015 with respect to this uncertainty.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	NOTE C - Summary of Significant Accounting Policies [1] Basis of Presentation The accompanying consolidated financial statements include the consolidated accounts of Matinas BioPharma Holdings Inc. “Holdings” and its wholly owned subsidiaries, Matinas BioPharma Inc. and Aquarius Biotechnologies, Inc. the operational subsidiaries of Holdings. The accompanying consolidated financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and reflect the operations of the Company and its wholly-owned subsidiary. All intercompany transactions have been eliminated in consolidation. [2] Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Certain accounting principles require subjective and complex judgments to be used in the preparation of f in ancial statements. Accordingly, a different financial presentation could result depending on the judgments, estimates, or assumptions that are used. Such estimates and assumptions include, but are not specif i cally lim ited to, those required in the assessment of the impairment of intangible assets and the va luati on of Level 3 fair value measurement of financial instruments and determination of stock-based compensat ion, contingent consideration and all acquired assets and liabilities. [3] Cash and Cash Equivalents The Company considers all highly liquid instruments purchased with original maturity of three months or less to be cash equivalents to the extent the funds are not being held for investment purposes. [4] Concentration of Credit Risk The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. Cash balances are maintained principally at one major U.S. financial institution and are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to regulatory limits. At all times throughout the year ended December 31, 2015, the Company’s cash balances exceeded the FDIC insurance limit. The Company has not experienced any losses in such accounts. [5] Equipment Equipment is stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. The estimated useful lives of the Company equipment ranges from three to ten years. Capitalized costs associated with leasehold improvements are depreciated over the lesser of the useful life of the asset or the remaining life of the lease. Income Taxes Deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates. The Company adopted the provisions of ASC 740-10 and has analyzed its filing positions in 2015 and 2014 in jurisdictions where it may be obligated to file returns. The Company believes that its income tax filing position and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position. Therefore, no reserves for uncertain income tax positions have been recorded. The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties as of December 31, 2015. In addition, future changes in unrecognized tax benefits will have no impact on the effective tax rate due to the existence of the valuation. Since the Company incurred net operating losses in every tax year since inception, the 2013, 2014 and 2015 income tax returns are subject to examination and adjustments by the IRS for at least three years following the year in which the tax attributes are utilized. Stock-Based Compensation The Company accounts for stock-based compensation to employees in conformity with the provisions of ASC Topic 718, “Stock Based Compensation” The Company accounts for equity instruments issued to non-employees in accordance with the provisions of ASC Topic 505, subtopic 50, Equity-Based Payments to Non-Employees The Company calculates the fair value of option grants utilizing the Black-Scholes pricing model, and estimates the fair value of restricted stock based upon the estimated fair value or the common stock. The amount of stockbased compensation recognized during a period is based on the value of the portion of the awards that are ultimately expected to vest. The authoritative guidance requires forfeitures to be estimated at the time stock options are granted and warrants are issued and revised. If necessary in subsequent periods, an adjustment will be booked if actual forfeitures differ from those estimated. The term “forfeitures” is distinct from “cancellations” or “expirations” and represents only the unvested portion of the surrendered stock option or warrant. The Company estimates forfeiture rates for all unvested awards when calculating the expense for the period. In estimating the forfeiture rate, the Company monitors both stock option and warrant exercises as well as employee and non-employee termination patterns. The resulting stock-based compensation expense for both employee and non-employee awards is generally recognized on a straight-line basis over the requisite service period of the award. Fair Value Measurements ASC 820 “Fair Value Measurements” defines fair value, establishes a framework for measuring fair value in GAAP and expands disclosures about fair value measurements. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC 820 establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy under ASC 820 are described below: • Level 1 - Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. • Level 2 - Directly or indirectly observable inputs as of the reporting date through correlation with market data, including quoted prices for similar assets and liabilities in active markets and quoted prices in markets that are not active. Level 2 also includes assets and liabilities that are valued using models or other pricing methodologies that do not require significant judgment since the input assumptions used in the models, such as interest rates and volatility factors, are corroborated by readily observable data from actively quoted markets for substantially the full term of the financial instrument. • Level 3 - Unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management’s estimates of market participant assumptions. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value. The carrying amounts of cash and cash equivalents, restricted cash, accounts payable and accrued expenses approximate fair value due to the short-term nature of these instruments. Earnings Per Share Basic earnings per common share is computed as net loss divided by the weighted average number of common shares outstanding during the period. Diluted earnings per common share is the same as basic earnings per common share because the Company incurred a net loss during each period presented, and the potentially dilutive securities from the assumed exercise of all outstanding stock options and warrants would have an antidilutive effect. 2015 2014 Stock Options 6,093,000 5,353,417 Warrants 39,250,000 15,250,000 Total 45,343,000 20,603,417 Revenue Recognition The Company recognizes revenue from the NIH contracts when the specified performance milestone is achieved. The milestones are analyzed and approved on a monthly basis through progress reports submitted by the Company. The existing NIH contracts ended in 2015. [11] Research and Development Research and development costs are charged to operations as they are incurred. Legal fees and other direct costs incurred in obtaining and protecting patents are also expensed as incurred, due to the uncertainty with respect to future cash flows resulting from the patents and our included as part of General and Administrative expenses. [12] Recent accounting pronouncements In September 2015, the FASB issued a new standard simplifying the accounting for measurement-period adjustments. The new standard eliminates the requirement to restate prior period financial statements for measurement period adjustments. The new standard requires that the cumulative impact of a measurement period adjustment (including the impact on prior periods) be recognized in the reporting period in which the adjustment is identified. The standard is effective for interim and annual periods beginning after December 15, 2015 and is not expected to have a material impact on our financial condition or results of operations. In November 2015, the FASB issued a new standard simplifying the classification of deferred tax assets and liabilities. The new standard requires that all deferred tax assets and liabilities, along with any related valuation allowance, be classified as noncurrent on the balance sheet. The standard is effective for interim and annual periods beginning after December 15, 2016 and allows for early adoption using a full retrospective method or a prospective method. We have elected to early adopt the provisions of this new standard using a prospective method. As a result, all deferred taxes as of December 31, 2015 are classified as noncurrent in our consolidated balance sheet, while prior periods remain as previously reported. As of December 31, 2015 there are no deferred tax assets. In 2014, the FASB issued ASU 2014-15, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.” This ASU describes how an entity should assess its ability to meet obligations and sets rules for how this information should be disclosed in the financial statements. The standard provides accounting guidance that will be used along with existing auditing standards. The ASU is effective for interim and annual periods beginning after December 15, 2016. Early application is permitted. The Corporation is in the process of evaluating the impact of this standard but does not expect this standard to have a material impact on the Corporation’s consolidated financial position or results of operation. [13] Business Combination The Company accounts for acquisitions using the acquisition method of accounting which requires the recognition of tangible and identifiable intangible assets acquired and liabilities assumed at their estimated fair values as of the business combination date. The Company allocates any excess purchase price over the estimated fair value assigned to the net tangible and identifiable intangible assets acquired and liabilities assumed to goodwill. Transaction costs are expensed as incurred in general and administrative expenses. Results of operations and cash flows of acquired companies are included in the Company's operating results from the date of acquisition. The Company's intangible assets are comprised of acquired in-process research and development, or IPR&D. The fair value of IPR&D acquired through a business combination is capitalized as an indefinite-lived intangible asset until the completion or abandonment of the related research and development activities. IPR&D is tested for impairment annually or when events or circumstances indicate that the fair value may be below the carrying value of the asset. There was no impairment for the year ended December 31, 2015. If and when research and development is complete, the associated assets would then be amortized over their estimated useful lives. Goodwill and other intangible assets Goodwill is assessed for impairment at least annually on a reporting unit basis, or more frequently when events and circumstances occur indicating that the recorded goodwill may be impaired. In accordance with the authoritative accounting guidance we have the option to perform a qualitative assessment to determine whether it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount. If we determine this is the case, we are required to perform the two-step goodwill impairment test to identify potential goodwill impairment and measure the amount of goodwill impairment loss to be recognized, if any. If we determine that it is more-likely-than-not that the fair value of the reporting unit is greater than its carrying amounts, the two-step goodwill impairment test is not required. As defined in the authoritative guidance, a reporting unit is an operating segment, or one level below an operating segment. Historically, we conducted our business in a single operating segment and reporting unit. In fiscal year 2015, we assessed goodwill impairment by performing a qualitative test for our reporting unit. Based on the results of our testing, it was determined that it is more-likely-than-not that the fair value of the reporting units are greater than their carrying amounts. There was no impairment of goodwill in fiscal year 2015. We review other intangible assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. The authoritative accounting guidance allows a qualitative approach for testing indefinite-lived intangible assets for impairment, similar to the impairment testing guidance for goodwill. It allows the option to first assess qualitative factors (events and circumstances) that could have affected the significant inputs used in determining the fair value of the indefinite-lived intangible asset. The qualitative factors assist in determining whether it is more-likely-than-not (i.e. > 50% chance) that the indefinite-lived intangible asset is impaired. An organization may choose to bypass the qualitative assessment for any indefinite-lived intangible asset in any period and proceed directly to calculating its fair value. Our indefinite-lived intangible assets are IPR&D intangible assets. In all other instances we used the qualitative test and concluded that it was more-likely-than-not that all other indefinite-lived assets were not impaired and therefore, there were no impairments in fiscal year 2015. Reclassification Contingent consideration arising from the acquisition of Aquarius is included as part of the purchase price and is recognized at fair value as of the acquisition date. See Note D below. During the quarter ended December 31, 2015, we reclassified the contingent consideration ($ 753 thousand) valued at the time of the Aquarius Acquisition (see Note D), from a long term liability to additional paid in capital in equity. We also reclass $ 48 2015.

Acquisition of Aquarius Biotech

Acquisition of Aquarius Biotechnologies, Inc.	12 Months Ended
	Dec. 31, 2015
Business Combinations [Abstract]
Business Combination Disclosure [Text Block]	NOTE D – Acquisition of Aquarius Biotechnologies, Inc. On January 29, 2015, we entered into the Merger Agreement with Aquarius, Saffron Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of ours (“Merger Sub”) and J. Carl Craft, as the stockholder representative. The merger contemplated by the Aquarius Merger became effective on January 29, 2015, following the satisfaction or waiver of the conditions described in the Merger Agreement, including approval of the transaction by 100 Pursuant to the terms of the Merger Agreement, we were obligated to issue an aggregate of up to 5,000,000 4,608,020 3,000,000 (i) 1,500,000 shares issuable upon the dosing of the first patient in a phase III trial sponsored by us for a product utilizing Aquarius’ proprietary cochleate delivery technology and (ii) 1,500,000 shares issuable upon FDA approval of the first NDA submitted by us for a product utilizing Aquarius’ proprietary cochleate delivery technology. As discussed in footnote (15) the Company ultimately concluded that the contingent share issuance represented equity settled contingent consideration and as such have reclassified the amounts to equity as of December 31, 2015. The transaction was accounted for as a business combination, and accordingly the Company has included the results of operations of Aquarius subsequent to the January 29, 2015 closing date. The transaction resulted in a significant amount of in-process research and development, goodwill and deferred tax liability on the balance sheet, as detailed below. 2,873,035 Fair value of 4,608,020 of common stock issued at a price per share of $0.46 as of January 29, 2015 the closing date of the merger. $ 2,119,689 Fair value of potential Matinas common stock as contingent consideration that will be issued upon achieving certain future clinical milestone-(a) 422,609 Fair value of potential Matinas common stock as contingent consideration that will be issued upon achieving certain future regulatory milestone-(a) 330,737 Total consideration $ 2,873,035 ( a)-Reflects recognition of the estimated fair value of the contingent consideration payable with issuance of Matinas common stock upon achievement of certain future clinical and regulatory milestones, the achievement of which is uncertain. The fair value of the additional shares were established by assigning probabilities and projected dates of positive outcome for the milestones and valuing the future issuance of the shares by using the Black-Scholes options pricing model to account for the uncertainty in the future value of the shares. The value of the shares as derived using the options pricing model were then weighted based on the probability of achieving the milestones to determine the fair market value of the additional shares. See footnote C-15 for additional details. Cash $ 70,754 Contract/ Grant receivable 45,644 Prepaid expenses and other current assets 5,084 Equipment, net 5,051 Other assets 700 In-process research and development-(b) 3,017,377 Total identifiable assets 3,144,610 Accounts payable 300,413 Notes payable-(d) 10,000 Accrued expenses 92,509 Total liabilities assumed 402,922 Net identifiable assets acquired 2,741,688 Goodwill-(c) 1,336,488 Deferred income taxes arising from basis differences of tax aspects of in-process research and development (1,205,141) Net assets acquired $ 2,873,035 value of the in-process research and development asset was estimated on the basis of its replacement cost as determined by a buildup of the costs incurred to develop the technology as it existed as of the acquisition date resulting in a fair value of $ 3,017,377 (c)-The Company allocated the purchase price to the net tangible and intangible assets based upon their estimated fair values at the Merger date. The excess of the purchase price over the estimated fair values of the net tangible and intangible assets acquired has been recorded as goodwill including deferred tax liabilities resulting from the tax attributes of the in-process research and development (see Note C 14). In connection with the Aquarius acquisition, the Company made an adjustment as a result of the purchase accounting requirements to reflect a change in the value of the deferred tax liabilities resulting from an adjustment to the Company's effective tax rate, recording a $48 thousand reduction to the deferred tax liabilities with an offsetting credit to Goodwill. (d)- Aquarius issued a note for a loan that was made to a related party. Interest on the note is calculated using the applicable federal rate for midterm loans. Since the note has no specified repayment terms, it is considered a current liability. This note was paid in full in 2015.

2015 Private Placement Funding

2015 Private Placement Funding	12 Months Ended
	Dec. 31, 2015
2015 Private Placement [Member]
2015 Private Placement Funding [Line Items]
Stockholders' Equity Note Disclosure [Text Block]	NOTE E – 2015 Private Placement Funding The Company had two closings for a private placement, on March 31, 2015 and April 10, 2015, respectively. This private placement offered to accredited investors (the “Offering”) of the Company’s units (the “Units”) at a price of $ 0.50 0.0001 0.75 3.00 In connection with the Offering, the Company also entered into definitive subscription agreements (the “Subscription Agreements”) with accredited investors (the “Investors”) and issued an aggregate of 20,000,000 20,000,000 10 8.5 In addition, the Company entered into a Registration Rights Agreement with the Investors pursuant to which the Company has granted the Investors certain registration rights which are described in more detail below. The Company entered into a Placement Agency Agreement with Aegis Capital Corp. (“Aegis”) pursuant to which Aegis acted as the Company’s exclusive placement agent (the “Placement Agent”) for the Offering. Immediately prior to the Offering, the Placement Agent and its affiliates beneficially owned an aggregate of more than 10% of our outstanding equity securities. In addition, Adam Stern, Head of Private Equity Banking at Aegis, is a member of the Company’s board of directors. Pursuant to the terms of the Placement Agency Agreement, in connection with the Offering, the Company paid the Placement Agent an aggregate cash fee of $ 1,000,000 300,000 2,000,000 0.50 2,000,000 0.75 5 Registration Rights Agreement In connection with the 2015 Private Placement, the Company entered into a registration rights agreement with the investors in the 2015 Private Placement pursuant to which the Company was required to file a registration statement covering the resale of the shares of common stock and the shares of common stock underlying the warrants within sixty days and to use commercially reasonable efforts to have the registration statement declared effective within 150 days. The Registration Statement was filed on June 9, 2015 and declared effective on July 23, 2015. The Company is required to keep the registration statement continuously effective under the Securities Act of 1933, as amended (the “Securities Act”), for a period of one year from the date it is declared effective by the SEC or for such shorter period ending on the earlier of the date when all the registrable securities covered by the registration statement have been sold or such time as all of the securities covered by the registration statement can be sold under Rule 144 without any volume limitations (the “Effectiveness Period”). If the Company does not maintain the effectiveness of the registration statement during the Effectiveness Period, subject to certain limitations and the right of the Company to suspend the use of the prospectus for certain periods, the Company shall pay to each holder of registrable securities purchased in 2015 Private Placement an amount in cash equal to half of one percent (0.5%) of such holder’s investment amount, subject to a maximum penalty equal to six percent (6%) of such holder’s investment amount, on every thirty (30) day anniversary of such failure to maintain the registration statement until such failure was cured; provided however that such liquidated damages shall be paid only with respect to registrable securities that cannot then be immediately resold in reliance on Rule 144.

Equipment

Equipment	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	NOTE F – Equipment December 31, December 31, 2015 2014 Lab Equipment $ 327 245 Furniture and Fixtures 20 20 Capitalized Leased Equipment 111 111 Leasehold Improvements 7 7 Total 465 383 Less accumulated depreciation 87 43 Equipment, net $ 378 $ 340 In 2014, the company entered a 24 1 885 1,379 44 42

Stock Holders Equity

Stock Holders Equity	12 Months Ended
	Dec. 31, 2015
Warrant [Member]
Stockholders' Equity Note Disclosure [Text Block]	NOTE G - Stock Holders Equity Warrants As of December 31, 2015, the Company had outstanding warrants to purchase an aggregate of 39,250,000 0.50 2.00 The Warrants are exercisable immediately upon issuance and have a five-year term. The Warrants may be exercised at any time in whole or in part upon payment of the applicable exercise price until expiration of the Warrants. No fractional shares will be issued upon the exercise of the Warrants. All of the Warrants may be exercised on a “cashless” basis in certain circumstances. However, since all such cashless exercises are settled on a net share basis, the exercise price and the number of warrant shares purchasable upon the exercise of the Investor Warrants are subject to adjustment upon the occurrence of certain events, which include stock dividends, stock splits, combinations and reclassifications of the Company capital stock or similar “organic changes” to the equity structure of the Company. Accordingly, pursuant to ASC 815, the warrants are classified as equity in the accompanying statement of stockholder’s Equity. The Company may call the Warrants, other than the Placement Agent Warrants, at any time the common stock trades above $ 5.00 3.00 Shares July 11, 2013 formation of Holdings, 4,000,000 warrants issued, terms 5 years, exercisable at $2.00, including 250,000 warrants sold to Mr. Adam Stern 4,000,000 July 11, 2013 recapitalization of Matinas BioPharma Inc. 1,000,000 warrants issued, terms 5 years, exercisable at $2.00 1,000,000 July and August 2013 completion of Private Placement, 7,500,000 warrants issued, terms 5 years, exercisable at $2.00 7,500,000 July 30, 2013 Placement Agent warrants issued as part of compensation for Private Placement. Terms 5 years, exercisable at $2.00 750,000 July 30, 2013 Placement Agent warrant issued as part of compensation for Private Placement. Terms 5 years exercisable at $1.00 1,500,000 July 30, 2013 500,000 warrants sold to Chairman of Board Mr. Herb Conrad for $20,000. Terms 5 years, exercisable at $2.00 per share 500,000 March 31, 2015 Warrants: March 31, 2015 first close of Private Placement, 9,875,0000 warrants issued, terms 5 years, exercisable at $0.75 9,875,000 March 31, 2015, Placement Agent Warrants, 987,500 issued, terms 5 years, exercisable at $0.75 987,500 March 31, 2015, Placement Agent Warrants, 987,500 issued, terms 5 years, exercisable at $ 0.50 987,500 April 10, 2015 Warrants: April 10, 2015 first close of Private Placement, 10,125,000 warrants issued, terms 5 years, exercisable at $0.75 10,125,000 April 10, 2015, Placement Agent Warrants, 1,012,500 issued, terms 5 years, exercisable at $0.75 1,012,500 April 10, 2015, Placement Agent Warrants, 1,012,500 issued, terms 5 years, exercisable at $0.50 1,012,500 Total Warrants Outstanding at December 31, 2015 39,250,000

Stock Based Compensation

Stock Based Compensation	12 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	NOTE H - Stock Based Compensation In August 2013, the Company adopted the 2013 Equity Compensation Plan (the “Plan”), which provides for the granting of incentive stock options, nonqualified stock options, restricted stock units, performance units, and stock purchase rights. Options under the Plan may be granted at prices not less than 100% of the fair value of the shares on the date of grant as determined by the Board Committee. The Board Committee determines the period over which the options become exercisable subject to certain restrictions as defined in the Plan, with the current outstanding options generally vesting over three years. The term of the options is no longer than ten years. The Company currently has reserved 9,541,706 With the approval of the Board of Directors and majority Shareholders, effective May 8, 2014, the Plan was amended and restated. The amendment provides for an automatic increase in the number of shares of common stock available for issuance under the Plan each January (with Board approval), commencing January 1, 2015 4 Year Ended December 31, 2015 2014 Research and Development $ 528 $ 398 General and Administrative 1,064 1,576 Total $ 1,592 $ 1,974 Stock Incentive Plans: Awards Reserved Awards for Awards Available Issuance Issued for Grant 2013 Equity Compensation Plan 9,541,706 7,474,434 * 2,067,272 * includes both stock grants and option grants Weighted average Weighted average Number of exercise contractual term in Options price years Outstanding at December 31, 2013 3,160 $ 0.94 9.7 Granted 2,413 $ 1.22 Exercised - Forfeited (196) 0.94 Expired (24) 0.96 Outstanding at December 31, 2014 5,353 $ 1.06 9.1 Granted 1,960 $ 0.56 Exercised - Forfeited (217) 0.95 Expired (193) 0.89 Outstanding at December 31, 2015 6,903 $ 0.93 8.4 Year ended December 31, 2015 2014 Options exercisable at end of year 3,752 2,460 Weighted average grant date fair value (per share) of options granted during the period $ 0.65 $ 0.68 All options expire ten years from date of grant. Except for options granted to consultants, all remaining options vest entirely and evenly over three years. A portion of options granted to consultants vests over four years, with the remaining vesting being based upon the achievement of certain performance milestones, which are tied to either financing or drug development initiatives. The Company recognizes compensation expense for stock option awards on a straight-line basis over the applicable service period of the award. The service period is generally the vesting period, with the exception of options granted subject to a consulting agreement, whereby the option vesting period and the service period defined pursuant to the terms of the consulting agreement may be different. Stock options issued to consultants are revalued quarterly until fully vested, with any change in fair value expensed. For the year ended December 31, 2015 2014 Volatility 71.10 % - 102.3 % 68.76 % Risk-free interest rate 1.34% - 1.74 % 1.65% - 1.93 % Dividend yield 0.0 % 0.0 % Expected life 6.0 years 4.75 – 5.5 years The Company does not have sufficient historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior. Hence, the Company uses the “simplified method” described in Staff Accounting Bulletin (SAB) 107 to estimated expected term of share option grants. The expected stock price volatility assumption was determined by examining the historical volatilities for industry peers, as the Company has limited history for the Company’s common stock. The Company will continue to analyze the historical stock price volatility and expected term assumptions as more historical data for the Company’s common stock becomes available. The risk-free interest rate assumption is based on the U.S treasury instruments whose term was consistent with the expected term of the Company’s stock options. The expected dividend assumption is based on the Company’s history and expectation of dividend payouts. The Company has never paid dividends on its common stock and does not anticipate paying dividends on its common stock in the foreseeable future. Accordingly, the Company has assumed no dividend yield for purposes of estimating the fair value of the Company share-based compensation. The Company estimates the forfeiture rate at the time of grant and revisions, if necessary, were estimated based on management’s expectation through industry knowledge and historical data. During the years ended December 31, 2015 and 2014, the Company issued 278,784 292,650 0.2 0.2 During the years ended December 31, 2014, the company met certain clinical milestones upon which 71,750 28,000 As of December 31, 2015, the aggregate intrinsic value of in the money options was $ 0.6 As of December 31, 2015, there was approximately $ 1.9 1.3

COMMMITMENTS

COMMMITMENTS	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	NOTE I – COMMMITMENTS On November 1, 2013, the Company entered into a 7 12,723 14,200 211,500 95,000 In December of 2015, the Company renewed its agreement to lease laboratory space for one year starting January 1, 2016 in Monmouth Junction, New Jersey at a monthly rent of $ 2,287 Fiscal Year Ending December 31, Lease Commitments 2016 184,520 2017 160,012 2018 162,948 2019 165,896 2020 and beyond 252,764 Total future minimum lease payments $ 926,140 The Company was obligated to provide a security deposit of $ 300,000 This deposit was reduced by $100,000 in 2015 and can be reduced by $ 100,000 on an annual basis going forward, down to $50,000, as long as the Company makes timely rental payments. Through our acquisition of Aquarius, we acquired a license from Rutgers University for the cochleate delivery technology. The Amended and Restated Exclusive License Agreement between Aquarius and Rutgers, The State University of New Jersey (successor in interest to the University of Medicine and Dentistry of New Jersey) provides for, among other things, (1) royalties on a tiered basis between low single digits and the mid-single digits of net sales of products using such licensed technology, (2) a one-time sales milestone fee of $ 100,000 10,000 50,000 The Company also has employment agreements with certain employees which require the funding of a specific level of payments, if certain events, such as a change in control, termination without cause or retirement, occur.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	NOTE J – Income Taxes The Company utilizes the liability method of accounting for deferred income taxes. Under this method, deferred tax liabilities and assets are recognized for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities. A valuation allowance is established against deferred tax assets when, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company's policy is to record interest and penalties on uncertain tax positions as income tax expense. As of December 31, 2015 and December 31, 2014, the Company does not believe any material uncertain tax positions were present. Accordingly, interest and penalties have not been accrued due to an uncertain tax position. Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Years ended December 31, 2,015 2,014 Percent of pre-tax income: U.S. federal statutory income tax rate 34.0 % 34.0 % State taxes, net of federal benefit 0.0 % 0.1 % Permanent items (5.3) % (3.1) % Research and development credit 3.0 % 0.9 % Change in valuation allowance (31.7) % (31.9) % Effective income tax rate 0.0 % 0.0 % The Company has no current income taxes payable other than certain state minimum taxes which are included in general and administrative expenses. As of December 31, 2015 2014 Deferred tax assets (liabilities) Share-based compensation $ 518,542 $ 489,017 Depreciation and amortization 37,186 73,894 Warrants 43,997 43,997 Accrued liability 118,386 - Net operating loss carryforwards 7,093,015 4,379,541 Federal research and development credit carryforwards 525,001 241,318 In process research and development (1,205,141) - Deferred income tax assets 7,130,986 5,227,767 Valuation allowance (8,336,127) (5,227,767) Net deferred tax liabilities $ (1,205,141) $ 0 In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of taxable income during the periods in which the temporary differences representing net future deductible amounts become deductible, and is impacted by the Company's ability to carryback losses to previous years in which the Company had taxable income. Due to the Company's history of losses and lack of other positive evidence to support taxable income, the Company has recorded a valuation allowance against those deferred tax assets that are not expected to be realized. The valuation allowance was approximately $ 8.3 5.2 3.1 As of December 31, 2015, the Company had Federal net operating loss carryforwards of $ 19.2 525,000 In December 2015, the Company recognized a tax benefit of approximately $ 760,000 Utilization of the net operating losses and general business tax credits carryforwards may be subject to a substantial limitation under Sections 382 and 383 of the Internal Revenue Code of 1986 due to changes in ownership of the Company that have occurred previously or that could occur in the future. These ownership changes may limit the amount of net operating losses and general business tax credits carryforwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50 percentage points over a three-year period. The Company has not completed a study to determine whether it had undergone an ownership change since the Company's inception. There was a change in accounting principle related to our early adoption of ASU 2015-17 on a prospective basis as of December 31, 2015. The adoption did not result in any increase or decrease to the Company's current or noncurrent assets or liabilities. The adoption of the ASU to classify all of our deferred tax assets and liabilities as noncurrent will reduce time, complexity and costs to prepare our tax disclosures related to deferred income taxes.

Summary of Significant Accoun17

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	[1] Basis of Presentation The accompanying consolidated financial statements include the consolidated accounts of Matinas BioPharma Holdings Inc. “Holdings” and its wholly owned subsidiaries, Matinas BioPharma Inc. and Aquarius Biotechnologies, Inc. the operational subsidiaries of Holdings. The accompanying consolidated financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and reflect the operations of the Company and its wholly-owned subsidiary. All intercompany transactions have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	[2] Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Certain accounting principles require subjective and complex judgments to be used in the preparation of f in ancial statements. Accordingly, a different financial presentation could result depending on the judgments, estimates, or assumptions that are used. Such estimates and assumptions include, but are not specif i cally lim ited to, those required in the assessment of the impairment of intangible assets and the va luati on of Level 3 fair value measurement of financial instruments and determination of stock-based compensat ion, contingent consideration and all acquired assets and liabilities.
Cash and Cash Equivalents, Policy [Policy Text Block]	[3] Cash and Cash Equivalents The Company considers all highly liquid instruments purchased with original maturity of three months or less to be cash equivalents to the extent the funds are not being held for investment purposes.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	[4] Concentration of Credit Risk The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. Cash balances are maintained principally at one major U.S. financial institution and are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to regulatory limits. At all times throughout the year ended December 31, 2015, the Company’s cash balances exceeded the FDIC insurance limit. The Company has not experienced any losses in such accounts.
Property, Plant and Equipment, Policy [Policy Text Block]	[5] Equipment Equipment is stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. The estimated useful lives of the Company equipment ranges from three to ten years. Capitalized costs associated with leasehold improvements are depreciated over the lesser of the useful life of the asset or the remaining life of the lease.
Income Tax, Policy [Policy Text Block]	Income Taxes Deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates. The Company adopted the provisions of ASC 740-10 and has analyzed its filing positions in 2015 and 2014 in jurisdictions where it may be obligated to file returns. The Company believes that its income tax filing position and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position. Therefore, no reserves for uncertain income tax positions have been recorded. The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties as of December 31, 2015. In addition, future changes in unrecognized tax benefits will have no impact on the effective tax rate due to the existence of the valuation. Since the Company incurred net operating losses in every tax year since inception, the 2013, 2014 and 2015 income tax returns are subject to examination and adjustments by the IRS for at least three years following the year in which the tax attributes are utilized.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation The Company accounts for stock-based compensation to employees in conformity with the provisions of ASC Topic 718, “Stock Based Compensation” The Company accounts for equity instruments issued to non-employees in accordance with the provisions of ASC Topic 505, subtopic 50, Equity-Based Payments to Non-Employees The Company calculates the fair value of option grants utilizing the Black-Scholes pricing model, and estimates the fair value of restricted stock based upon the estimated fair value or the common stock. The amount of stockbased compensation recognized during a period is based on the value of the portion of the awards that are ultimately expected to vest. The authoritative guidance requires forfeitures to be estimated at the time stock options are granted and warrants are issued and revised. If necessary in subsequent periods, an adjustment will be booked if actual forfeitures differ from those estimated. The term “forfeitures” is distinct from “cancellations” or “expirations” and represents only the unvested portion of the surrendered stock option or warrant. The Company estimates forfeiture rates for all unvested awards when calculating the expense for the period. In estimating the forfeiture rate, the Company monitors both stock option and warrant exercises as well as employee and non-employee termination patterns. The resulting stock-based compensation expense for both employee and non-employee awards is generally recognized on a straight-line basis over the requisite service period of the award.
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements ASC 820 “Fair Value Measurements” defines fair value, establishes a framework for measuring fair value in GAAP and expands disclosures about fair value measurements. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC 820 establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy under ASC 820 are described below: • Level 1 - Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. • Level 2 - Directly or indirectly observable inputs as of the reporting date through correlation with market data, including quoted prices for similar assets and liabilities in active markets and quoted prices in markets that are not active. Level 2 also includes assets and liabilities that are valued using models or other pricing methodologies that do not require significant judgment since the input assumptions used in the models, such as interest rates and volatility factors, are corroborated by readily observable data from actively quoted markets for substantially the full term of the financial instrument. • Level 3 - Unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management’s estimates of market participant assumptions. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value. The carrying amounts of cash and cash equivalents, restricted cash, accounts payable and accrued expenses approximate fair value due to the short-term nature of these instruments.
Earnings Per Share, Policy [Policy Text Block]	Earnings Per Share Basic earnings per common share is computed as net loss divided by the weighted average number of common shares outstanding during the period. Diluted earnings per common share is the same as basic earnings per common share because the Company incurred a net loss during each period presented, and the potentially dilutive securities from the assumed exercise of all outstanding stock options and warrants would have an antidilutive effect. 2015 2014 Stock Options 6,093,000 5,353,417 Warrants 39,250,000 15,250,000 Total 45,343,000 20,603,417
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company recognizes revenue from the NIH contracts when the specified performance milestone is achieved. The milestones are analyzed and approved on a monthly basis through progress reports submitted by the Company. The existing NIH contracts ended in 2015.
Research and Development Expense, Policy [Policy Text Block]	[11] Research and Development Research and development costs are charged to operations as they are incurred. Legal fees and other direct costs incurred in obtaining and protecting patents are also expensed as incurred, due to the uncertainty with respect to future cash flows resulting from the patents and our included as part of General and Administrative expenses.
New Accounting Pronouncements, Policy [Policy Text Block]	[12] Recent accounting pronouncements In September 2015, the FASB issued a new standard simplifying the accounting for measurement-period adjustments. The new standard eliminates the requirement to restate prior period financial statements for measurement period adjustments. The new standard requires that the cumulative impact of a measurement period adjustment (including the impact on prior periods) be recognized in the reporting period in which the adjustment is identified. The standard is effective for interim and annual periods beginning after December 15, 2015 and is not expected to have a material impact on our financial condition or results of operations. In November 2015, the FASB issued a new standard simplifying the classification of deferred tax assets and liabilities. The new standard requires that all deferred tax assets and liabilities, along with any related valuation allowance, be classified as noncurrent on the balance sheet. The standard is effective for interim and annual periods beginning after December 15, 2016 and allows for early adoption using a full retrospective method or a prospective method. We have elected to early adopt the provisions of this new standard using a prospective method. As a result, all deferred taxes as of December 31, 2015 are classified as noncurrent in our consolidated balance sheet, while prior periods remain as previously reported. As of December 31, 2015 there are no deferred tax assets. In 2014, the FASB issued ASU 2014-15, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.” This ASU describes how an entity should assess its ability to meet obligations and sets rules for how this information should be disclosed in the financial statements. The standard provides accounting guidance that will be used along with existing auditing standards. The ASU is effective for interim and annual periods beginning after December 15, 2016. Early application is permitted. The Corporation is in the process of evaluating the impact of this standard but does not expect this standard to have a material impact on the Corporation’s consolidated financial position or results of operation.
Business Combinations Policy [Policy Text Block]	[13] Business Combination The Company accounts for acquisitions using the acquisition method of accounting which requires the recognition of tangible and identifiable intangible assets acquired and liabilities assumed at their estimated fair values as of the business combination date. The Company allocates any excess purchase price over the estimated fair value assigned to the net tangible and identifiable intangible assets acquired and liabilities assumed to goodwill. Transaction costs are expensed as incurred in general and administrative expenses. Results of operations and cash flows of acquired companies are included in the Company's operating results from the date of acquisition. The Company's intangible assets are comprised of acquired in-process research and development, or IPR&D. The fair value of IPR&D acquired through a business combination is capitalized as an indefinite-lived intangible asset until the completion or abandonment of the related research and development activities. IPR&D is tested for impairment annually or when events or circumstances indicate that the fair value may be below the carrying value of the asset. There was no impairment for the year ended December 31, 2015. If and when research and development is complete, the associated assets would then be amortized over their estimated useful lives.
Goodwill and Intangible Assets, Policy [Policy Text Block]	Goodwill and other intangible assets Goodwill is assessed for impairment at least annually on a reporting unit basis, or more frequently when events and circumstances occur indicating that the recorded goodwill may be impaired. In accordance with the authoritative accounting guidance we have the option to perform a qualitative assessment to determine whether it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount. If we determine this is the case, we are required to perform the two-step goodwill impairment test to identify potential goodwill impairment and measure the amount of goodwill impairment loss to be recognized, if any. If we determine that it is more-likely-than-not that the fair value of the reporting unit is greater than its carrying amounts, the two-step goodwill impairment test is not required. As defined in the authoritative guidance, a reporting unit is an operating segment, or one level below an operating segment. Historically, we conducted our business in a single operating segment and reporting unit. In fiscal year 2015, we assessed goodwill impairment by performing a qualitative test for our reporting unit. Based on the results of our testing, it was determined that it is more-likely-than-not that the fair value of the reporting units are greater than their carrying amounts. There was no impairment of goodwill in fiscal year 2015. We review other intangible assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. The authoritative accounting guidance allows a qualitative approach for testing indefinite-lived intangible assets for impairment, similar to the impairment testing guidance for goodwill. It allows the option to first assess qualitative factors (events and circumstances) that could have affected the significant inputs used in determining the fair value of the indefinite-lived intangible asset. The qualitative factors assist in determining whether it is more-likely-than-not (i.e. > 50% chance) that the indefinite-lived intangible asset is impaired. An organization may choose to bypass the qualitative assessment for any indefinite-lived intangible asset in any period and proceed directly to calculating its fair value. Our indefinite-lived intangible assets are IPR&D intangible assets. In all other instances we used the qualitative test and concluded that it was more-likely-than-not that all other indefinite-lived assets were not impaired and therefore, there were no impairments in fiscal year 2015.
Business Combination, Contingent Consideration, Liability [Policy Text Block]	Reclassification Contingent consideration arising from the acquisition of Aquarius is included as part of the purchase price and is recognized at fair value as of the acquisition date. See Note D below. During the quarter ended December 31, 2015, we reclassified the contingent consideration ($ 753 thousand) valued at the time of the Aquarius Acquisition (see Note D), from a long term liability to additional paid in capital in equity. We also reclass $ 48 2015.

Summary of Significant Accoun18

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	The following schedule details the number of shares issuable upon the exercise of stock options and warrants, which have been excluded from the diluted loss per share calculation for the years ended December 31, 2015 and 2014: 2015 2014 Stock Options 6,093,000 5,353,417 Warrants 39,250,000 15,250,000 Total 45,343,000 20,603,417

Acquisition of Aquarius Biote19

Acquisition of Aquarius Biotechnologies, Inc. (Tables)	12 Months Ended
	Dec. 31, 2015
Business Combinations [Abstract]
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	2,873,035 Fair value of 4,608,020 of common stock issued at a price per share of $0.46 as of January 29, 2015 the closing date of the merger. $ 2,119,689 Fair value of potential Matinas common stock as contingent consideration that will be issued upon achieving certain future clinical milestone-(a) 422,609 Fair value of potential Matinas common stock as contingent consideration that will be issued upon achieving certain future regulatory milestone-(a) 330,737 Total consideration $ 2,873,035 ( a)-Reflects recognition of the estimated fair value of the contingent consideration payable with issuance of Matinas common stock upon achievement of certain future clinical and regulatory milestones, the achievement of which is uncertain. The fair value of the additional shares were established by assigning probabilities and projected dates of positive outcome for the milestones and valuing the future issuance of the shares by using the Black-Scholes options pricing model to account for the uncertainty in the future value of the shares. The value of the shares as derived using the options pricing model were then weighted based on the probability of achieving the milestones to determine the fair market value of the additional shares. See footnote C-15 for additional details.
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	Cash $ 70,754 Contract/ Grant receivable 45,644 Prepaid expenses and other current assets 5,084 Equipment, net 5,051 Other assets 700 In-process research and development-(b) 3,017,377 Total identifiable assets 3,144,610 Accounts payable 300,413 Notes payable-(d) 10,000 Accrued expenses 92,509 Total liabilities assumed 402,922 Net identifiable assets acquired 2,741,688 Goodwill-(c) 1,336,488 Deferred income taxes arising from basis differences of tax aspects of in-process research and development (1,205,141) Net assets acquired $ 2,873,035 (b)-The fair value of the in-process research and development asset was estimated on the basis of its replacement cost as determined by a buildup of the costs incurred to develop the technology as it existed as of the acquisition date resulting in a fair value of $ 3,017,377 (c)-The Company allocated the purchase price to the net tangible and intangible assets based upon their estimated fair values at the Merger date. The excess of the purchase price over the estimated fair values of the net tangible and intangible assets acquired has been recorded as goodwill including deferred tax liabilities resulting from the tax attributes of the in-process research and development (see Note C 14). In connection with the Aquarius acquisition, the Company made an adjustment as a result of the purchase accounting requirements to reflect a change in the value of the deferred tax liabilities resulting from an adjustment to the Company's effective tax rate, recording a $48 thousand reduction to the deferred tax liabilities with an offsetting credit to Goodwill. (d)- Aquarius issued a note for a loan that was made to a related party. Interest on the note is calculated using the applicable federal rate for midterm loans. Since the note has no specified repayment terms, it is considered a current liability. This note was paid in full in 2015.

Equipment (Tables)

Equipment (Tables)	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Fixed assets, summarized by major category, consist of the following ($ in thousands) for the year ended: December 31, December 31, 2015 2014 Lab Equipment $ 327 245 Furniture and Fixtures 20 20 Capitalized Leased Equipment 111 111 Leasehold Improvements 7 7 Total 465 383 Less accumulated depreciation 87 43 Equipment, net $ 378 $ 340

Stock Holders Equity (Tables)

Stock Holders Equity (Tables)	12 Months Ended
	Dec. 31, 2015
Stockholders Equity Note [Abstract]
Schedule of Stockholders Equity Note, Warrants or Rights [Table Text Block]	A summary of equity warrants outstanding as of December 31, 2015 is presented below, all of which are fully vested. Shares July 11, 2013 formation of Holdings, 4,000,000 warrants issued, terms 5 years, exercisable at $2.00, including 250,000 warrants sold to Mr. Adam Stern 4,000,000 July 11, 2013 recapitalization of Matinas BioPharma Inc. 1,000,000 warrants issued, terms 5 years, exercisable at $2.00 1,000,000 July and August 2013 completion of Private Placement, 7,500,000 warrants issued, terms 5 years, exercisable at $2.00 7,500,000 July 30, 2013 Placement Agent warrants issued as part of compensation for Private Placement. Terms 5 years, exercisable at $2.00 750,000 July 30, 2013 Placement Agent warrant issued as part of compensation for Private Placement. Terms 5 years exercisable at $1.00 1,500,000 July 30, 2013 500,000 warrants sold to Chairman of Board Mr. Herb Conrad for $20,000. Terms 5 years, exercisable at $2.00 per share 500,000 March 31, 2015 Warrants: March 31, 2015 first close of Private Placement, 9,875,0000 warrants issued, terms 5 years, exercisable at $0.75 9,875,000 March 31, 2015, Placement Agent Warrants, 987,500 issued, terms 5 years, exercisable at $0.75 987,500 March 31, 2015, Placement Agent Warrants, 987,500 issued, terms 5 years, exercisable at $ 0.50 987,500 April 10, 2015 Warrants: April 10, 2015 first close of Private Placement, 10,125,000 warrants issued, terms 5 years, exercisable at $0.75 10,125,000 April 10, 2015, Placement Agent Warrants, 1,012,500 issued, terms 5 years, exercisable at $0.75 1,012,500 April 10, 2015, Placement Agent Warrants, 1,012,500 issued, terms 5 years, exercisable at $0.50 1,012,500 Total Warrants Outstanding at December 31, 2015 39,250,000

Stock Based Compensation (Table

Stock Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	The Company recognized stock-based compensation expense (options, and restricted share grants) in its consolidated statements of operations as follows ($ in thousands): Year Ended December 31, 2015 2014 Research and Development $ 528 $ 398 General and Administrative 1,064 1,576 Total $ 1,592 $ 1,974
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	The following table contains information about the Company’s stock plan at December 31, 2015: Awards Reserved Awards for Awards Available Issuance Issued for Grant 2013 Equity Compensation Plan 9,541,706 7,474,434 * 2,067,272 * includes both stock grants and option grants
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	The following table summarizes the Company’ stock option activity and related information for the years ended December 31, 2014 and 2015 (number of options in thousands): Weighted average Weighted average Number of exercise contractual term in Options price years Outstanding at December 31, 2013 3,160 $ 0.94 9.7 Granted 2,413 $ 1.22 Exercised - Forfeited (196) 0.94 Expired (24) 0.96 Outstanding at December 31, 2014 5,353 $ 1.06 9.1 Granted 1,960 $ 0.56 Exercised - Forfeited (217) 0.95 Expired (193) 0.89 Outstanding at December 31, 2015 6,903 $ 0.93 8.4 Year ended December 31, 2015 2014 Options exercisable at end of year 3,752 2,460 Weighted average grant date fair value (per share) of options granted during the period $ 0.65 $ 0.68
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The following weighted-average assumptions were used to calculate share based compensation for the full year ended: For the year ended December 31, 2015 2014 Volatility 71.10 % - 102.3 % 68.76 % Risk-free interest rate 1.34% - 1.74 % 1.65% - 1.93 % Dividend yield 0.0 % 0.0 % Expected life 6.0 years 4.75 – 5.5 years

COMMMITMENTS (Tables)

COMMMITMENTS (Tables)	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Contractual Obligation, Fiscal Year Maturity Schedule [Table Text Block]	Fiscal Year Ending December 31, Lease Commitments 2016 184,520 2017 160,012 2018 162,948 2019 165,896 2020 and beyond 252,764 Total future minimum lease payments $ 926,140

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	A reconciliation of the statutory U.S. federal rate to the Company's effective tax rate is as follows: Years ended December 31, 2,015 2,014 Percent of pre-tax income: U.S. federal statutory income tax rate 34.0 % 34.0 % State taxes, net of federal benefit 0.0 % 0.1 % Permanent items (5.3) % (3.1) % Research and development credit 3.0 % 0.9 % Change in valuation allowance (31.7) % (31.9) % Effective income tax rate 0.0 % 0.0 %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	Significant components of the Company's deferred tax assets (liabilities) for 2015 and 2014 consist of the following: As of December 31, 2015 2014 Deferred tax assets (liabilities) Share-based compensation $ 518,542 $ 489,017 Depreciation and amortization 37,186 73,894 Warrants 43,997 43,997 Accrued liability 118,386 - Net operating loss carryforwards 7,093,015 4,379,541 Federal research and development credit carryforwards 525,001 241,318 In process research and development (1,205,141) - Deferred income tax assets 7,130,986 5,227,767 Valuation allowance (8,336,127) (5,227,767) Net deferred tax liabilities $ (1,205,141) $ 0

Nature of Business (Details Tex

Nature of Business (Details Textual) - USD ($) $ in Millions	Apr. 10, 2015	Jul. 11, 2013
Private Placement [Member]
Company Information And History [Line Items]
Stock Issued During Period, Shares, New Issues		15,000,000
Warrants Issued For Purchase Of Common Stock		7,500,000
Holdings [Member]
Company Information And History [Line Items]
Stock Issued During Period, Shares, New Issues		9,000,000
Warrants Issued For Purchase Of Common Stock		1,000,000
2015 Private Placement [Member]
Company Information And History [Line Items]
Stock Issued During Period, Shares, New Issues	20,000,000
Warrants Issued For Purchase Of Common Stock	20,000,000
Proceeds from Issuance of Private Placement	$ 8.5

Going Concern and Plan of Ope26

Going Concern and Plan of Operation (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Going Concern And Plan Of Operation [Line Items]
Deficit accumulated during development stage	$ (23,187,164)	$ (14,051,764)
Net loss	$ (9,135,400)	$ (10,221,045)

Summary of Significant Accoun27

Summary of Significant Accounting Policies (Details) - shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	45,343,000	20,603,417
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,093,000	5,353,417
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	39,250,000	15,250,000

Summary of Significant Accoun28

Summary of Significant Accounting Policies (Details Textual) $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)
Summary Of Significant Accounting Policies [Line Items]
Goodwill, Subsequent Recognition of Deferred Tax Asset	$ 48
Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life	10 years

Acquisition of Aquarius Biote29

Acquisition of Aquarius Biotechnologies, Inc. (Details) - Aquarius Biotechnologies, Inc. [Member]	1 Months Ended
	Jan. 29, 2015USD ($)
Business Acquisition [Line Items]
Fair value of 4,608,020 of common stock issued at a price per share of $0.46 as of January 29, 2015 the closing date of the merger.	$ 2,119,689
Fair value of potential Matinas common stock as contingent consideration that will be issued upon achieving certain future clinical milestone	422,609	[1]
Fair value of potential Matinas common stock as contingent consideration that will be issued upon achieving certain future regulatory milestone	330,737	[1]
Total consideration	$ 2,873,035
[1]	Reflects recognition of the estimated fair value of the contingent consideration payable with issuance of Matinas common stock upon achievement of certain future clinical and regulatory milestones, the achievement of which is uncertain. The fair value of the additional shares were established by assigning probabilities and projected dates of positive outcome for the milestones and valuing the future issuance of the shares by using the Black-Scholes options pricing model to account for the uncertainty in the future value of the shares. The value of the shares as derived using the options pricing model were then weighted based on the probability of achieving the milestones to determine the fair market value of the additional shares. See footnote C-15 for additional details.

Acquisition of Aquarius Biote30

Acquisition of Aquarius Biotechnologies, Inc. (Details 1) - USD ($)		Dec. 31, 2015	Jan. 29, 2015	Dec. 31, 2014
Business Acquisition [Line Items]
Goodwill		$ 1,336,488		$ 0
Net assets acquired			$ 2,873,035
Aquarius Biotechnologies, Inc. [Member]
Business Acquisition [Line Items]
Cash			70,754
Contract/ Grant receivable			45,644
Prepaid expenses and other current assets			5,084
Equipment, net			5,051
Other assets			700
In-process research and development	[1]		3,017,377
Total identifiable assets			3,144,610
Accounts payable			300,413
Notes payable	[2]		10,000
Accrued expenses			92,509
Total liabilities assumed			402,922
Net identifiable assets acquired			2,741,688
Goodwill	[3]		1,336,488
Deferred income taxes arising from basis differences of tax aspects of in-process research and development			(1,205,141)
Net assets acquired			$ 2,873,035
[1]	The fair value of the in-process research and development asset was estimated on the basis of its replacement cost as determined by a buildup of the costs incurred to develop the technology as it existed as of the acquisition date resulting in a fair value of $3,017,377. The fair value of other assets and liabilities approximate their book value.
[2]	Aquarius issued a note for a loan that was made to a related party. Interest on the note is calculated using the applicable federal rate for midterm loans. Since the note has no specified repayment terms, it is considered a current liability. This note was paid in full in 2015.
[3]	The Company allocated the purchase price to the net tangible and intangible assets based upon their estimated fair values at the Merger date. The excess of the purchase price over the estimated fair values of the net tangible and intangible assets acquired has been recorded as goodwill including deferred tax liabilities resulting from the tax attributes of the in-process research and development (see Note C 14). In connection with the Aquarius acquisition, the Company made an adjustment as a result of the purchase accounting requirements to reflect a change in the value of the deferred tax liabilities resulting from an adjustment to the Company's effective tax rate, recording a $48 thousand reduction to the deferred tax liabilities with an offsetting credit to Goodwill.

Acquisition of Aquarius Biote31

Acquisition of Aquarius Biotechnologies, Inc. (Details Textual) - USD ($)	1 Months Ended	12 Months Ended
	Jan. 29, 2015	Dec. 31, 2015	Dec. 31, 2014
Business Acquisition [Line Items]
Percentage Of Approval Shareholders	100.00%
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net	$ 2,873,035
Indefinite-Lived Intangible Assets (Excluding Goodwill)		$ 3,017,377	$ 0
Goodwill, Subsequent Recognition of Deferred Tax Asset		$ 48,000
Aquarius Biotechnologies, Inc. [Member]
Business Acquisition [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	4,608,020
Business Acquisition, Share Price	$ 0.46
Business Combination, Contingent Consideration, Upon Achieving Certain Future Clinical Milestone, Number of Shares Issuable	5,000,000
Business Combination, Contingent Consideration, Upon Achieving Certain Future Regulatory Milestone, Number of Shares Issuable	3,000,000
Milestone Consideration Description	(i) 1,500,000 shares issuable upon the dosing of the first patient in a phase III trial sponsored by us for a product utilizing Aquarius proprietary cochleate delivery technology and (ii) 1,500,000 shares issuable upon FDA approval of the first NDA submitted by us for a product utilizing Aquarius proprietary cochleate delivery technology. As discussed in footnote (15) the Company ultimately concluded that the contingent share issuance represented equity settled contingent consideration and as such have reclassified the amounts to equity as of December 31, 2015.
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net	$ 2,873,035

2015 Private Placement Funding

2015 Private Placement Funding (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Private Placement Funding [Line Items]
Common Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Effectiveness Of Registration Statement Description	The Registration Statement was filed on June 9, 2015 and declared effective on July 23, 2015. The Company is required to keep the registration statement continuously effective under the Securities Act of 1933, as amended (the Securities Act), for a period of one year from the date it is declared effective by the SEC or for such shorter period ending on the earlier of the date when all the registrable securities covered by the registration statement have been sold or such time as all of the securities covered by the registration statement can be sold under Rule 144 without any volume limitations (the Effectiveness Period). If the Company does not maintain the effectiveness of the registration statement during the Effectiveness Period, subject to certain limitations and the right of the Company to suspend the use of the prospectus for certain periods, the Company shall pay to each holder of registrable securities purchased in 2015 Private Placement an amount in cash equal to half of one percent (0.5%) of such holders investment amount, subject to a maximum penalty equal to six percent (6%) of such holders investment amount, on every thirty (30) day anniversary of such failure to maintain the registration statement until such failure was cured; provided however that such liquidated damages shall be paid only with respect to registrable securities that cannot then be immediately resold in reliance on Rule 144.
Proceeds from Issuance of Common Stock, Net	$ 8,500,000
Warrant [Member]
Private Placement Funding [Line Items]
Number Of Units Issued In Offering	20,000,000
Minimum [Member]
Private Placement Funding [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.50
2015 Private Placement [Member]
Private Placement Funding [Line Items]
Share Price	0.50
Common Stock, Par or Stated Value Per Share	0.0001
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.75
Warrant To Purchase Common Stock Period	5 years
Number Of Units Issued In Offering	20,000,000
Payments for Repurchase of Common Stock	$ 10,000,000
Placement Agent Fees	1,000,000
Non Accountable Expense Allowance	$ 300,000
Warrant Solicitation Fee Percentage	5.00%
2015 Private Placement [Member] | Exercise Price One [Member]
Private Placement Funding [Line Items]
Warrants Issued For Purchase Of Common Stock	2,000,000
Investment Warrants, Exercise Price	$ 0.50
2015 Private Placement [Member] | Exercise Price Two [Member]
Private Placement Funding [Line Items]
Warrants Issued For Purchase Of Common Stock	2,000,000
Investment Warrants, Exercise Price	$ 0.75
2015 Private Placement [Member] | Minimum [Member]
Private Placement Funding [Line Items]
Closing Bid Price Of Common Stock	$ 3

Equipment (Details)

Equipment (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 465,000	$ 383,000
Less accumulated depreciation	87,000	43,000
Equipment, net	377,723	339,995
Lab Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	327,000	245,000
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	20,000	20,000
Capitalized Leased Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	111,000	111,000
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 7,000	$ 7,000

Equipment (Details Textual)

Equipment (Details Textual) - USD ($)	1 Months Ended	12 Months Ended
	Jan. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Capitalized Leasing Term	24 months
Buyout, Option Cost Charged to Expense	$ 1
Interest Expense, Lessee, Assets under Capital Lease		$ 885	$ 1,379
Depreciation		$ 44,000	$ 42,000
Description of Lessee Leasing Arrangements, Capital Leases		The payments under the lease will be accounted for as interest and payments under capital lease using 2-year amortization

Stock Holders Equity (Details)

Stock Holders Equity (Details)	Dec. 31, 2015shares
Stock Holders Equity [Line Items]
Total Warrants Outstanding	39,250,000
July 11, 2013 Issue 1 [Member]
Stock Holders Equity [Line Items]
Total Warrants Outstanding	4,000,000
July 11, 2013 Issue 2 [Member]
Stock Holders Equity [Line Items]
Total Warrants Outstanding	1,000,000
July And August, 2013 [Member]
Stock Holders Equity [Line Items]
Total Warrants Outstanding	7,500,000
July 30, 2013 Issue 1 [Member]
Stock Holders Equity [Line Items]
Total Warrants Outstanding	750,000
July 30, 2013 Issue 2 [Member]
Stock Holders Equity [Line Items]
Total Warrants Outstanding	1,500,000
July 30, 2013 Issue 3 [Member]
Stock Holders Equity [Line Items]
Total Warrants Outstanding	500,000
March 31, 2015 Issue 1 [Member]
Stock Holders Equity [Line Items]
Total Warrants Outstanding	9,875,000
March 31, 2015 Issue 2 [Member]
Stock Holders Equity [Line Items]
Total Warrants Outstanding	987,500
March 31, 2015 Issue 3 [Member]
Stock Holders Equity [Line Items]
Total Warrants Outstanding	987,500
April 10, 2015 Issue 1 [Member]
Stock Holders Equity [Line Items]
Total Warrants Outstanding	10,125,000
April 10, 2015 Issue 2 [Member]
Stock Holders Equity [Line Items]
Total Warrants Outstanding	1,012,500
April 10, 2015 Issue 3 [Member]
Stock Holders Equity [Line Items]
Total Warrants Outstanding	1,012,500

Stock Holders Equity (Details T

Stock Holders Equity (Details Textual) - USD ($)	Apr. 10, 2015	Jul. 11, 2013	Mar. 31, 2015	Jul. 30, 2013	Aug. 31, 2013	Dec. 31, 2015
Stock Holders Equity [Line Items]
Class of Warrant or Right, Outstanding						39,250,000
Issuance Of Warrants Description						The Company may call the Warrants, other than the Placement Agent Warrants, at any time the common stock trades above $5.00 ( for 13 million investor/formation warrants ) or above $ 3.00 (for 20 million investor warrants) for twenty (20) consecutive days following the effectiveness of the registration statement covering the resale of the shares of common stock underlying the Warrants
July 11, 2013 Issue 1 [Member]
Stock Holders Equity [Line Items]
Class of Warrant or Right, Outstanding						4,000,000
July 11, 2013 Issue 2 [Member]
Stock Holders Equity [Line Items]
Class of Warrant or Right, Outstanding						1,000,000
July And August, 2013 [Member]
Stock Holders Equity [Line Items]
Class of Warrant or Right, Outstanding						7,500,000
July 30, 2013 Issue 1 [Member]
Stock Holders Equity [Line Items]
Class of Warrant or Right, Outstanding						750,000
July 30, 2013 Issue 2 [Member]
Stock Holders Equity [Line Items]
Class of Warrant or Right, Outstanding						1,500,000
July 30, 2013 Issue 3 [Member]
Stock Holders Equity [Line Items]
Class of Warrant or Right, Outstanding						500,000
March 31, 2015 Issue 1 [Member]
Stock Holders Equity [Line Items]
Class of Warrant or Right, Outstanding						9,875,000
March 31, 2015 Issue 2 [Member]
Stock Holders Equity [Line Items]
Class of Warrant or Right, Outstanding						987,500
March 31, 2015 Issue 3 [Member]
Stock Holders Equity [Line Items]
Class of Warrant or Right, Outstanding						987,500
April 10, 2015 Issue 1 [Member]
Stock Holders Equity [Line Items]
Class of Warrant or Right, Outstanding						10,125,000
April 10, 2015 Issue 2 [Member]
Stock Holders Equity [Line Items]
Class of Warrant or Right, Outstanding						1,012,500
April 10, 2015 Issue 3 [Member]
Stock Holders Equity [Line Items]
Class of Warrant or Right, Outstanding						1,012,500
Adam Stern [Member] | July 11, 2013 Issue 1 [Member]
Stock Holders Equity [Line Items]
Warrants Maturity Term		5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 2
Class of Warrant or Right, Outstanding		250,000
Matinas BioPharma Inc [Member] | July 11, 2013 Issue 2 [Member]
Stock Holders Equity [Line Items]
Warrants Maturity Term		5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 2
Private Placement Agent [Member] | July And August, 2013 [Member]
Stock Holders Equity [Line Items]
Warrants Maturity Term					5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 2
Private Placement Agent [Member] | July 30, 2013 Issue 1 [Member]
Stock Holders Equity [Line Items]
Warrants Maturity Term				5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 2
Private Placement Agent [Member] | July 30, 2013 Issue 2 [Member]
Stock Holders Equity [Line Items]
Warrants Maturity Term				5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 1
Private Placement Agent [Member] | March 31, 2015 Issue 1 [Member]
Stock Holders Equity [Line Items]
Warrants Maturity Term			5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.75
Private Placement Agent [Member] | March 31, 2015 Issue 2 [Member]
Stock Holders Equity [Line Items]
Warrants Maturity Term			5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.75
Private Placement Agent [Member] | March 31, 2015 Issue 3 [Member]
Stock Holders Equity [Line Items]
Warrants Maturity Term			5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.50
Private Placement Agent [Member] | April 10, 2015 Issue 1 [Member]
Stock Holders Equity [Line Items]
Warrants Maturity Term	5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.75
Mr.Herb Conrad [Member] | July 30, 2013 Issue 3 [Member]
Stock Holders Equity [Line Items]
Warrants Maturity Term				5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 2
Warrants and Rights Outstanding				$ 20,000
Placement Agent [Member] | Investor Warrants Thirteen Million [Member]
Stock Holders Equity [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 5
Placement Agent [Member] | Investor Warrants Twenty Million [Member]
Stock Holders Equity [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights						3
Placement Agent [Member] | April 10, 2015 Issue 2 [Member]
Stock Holders Equity [Line Items]
Warrants Maturity Term	5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.75
Placement Agent [Member] | April 10, 2015 Issue 3 [Member]
Stock Holders Equity [Line Items]
Warrants Maturity Term	5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.50
Maximum [Member]
Stock Holders Equity [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights						2
Minimum [Member]
Stock Holders Equity [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 0.50

Stock Based Compensation (Detai

Stock Based Compensation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated Share-based Compensation Expense	$ 1,592	$ 1,974
Research and development
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated Share-based Compensation Expense	528	398
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated Share-based Compensation Expense	$ 1,064	$ 1,576

Stock Based Compensation (Det38

Stock Based Compensation (Details 1) - 2013 Equity Compensation Plan [Member]	12 Months Ended
	Dec. 31, 2015shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards Reserved for Issuance	9,541,706
Awards Issued	7,474,434	[1]
Awards Available for Grant	2,067,272
[1]	includes both stock grants and option grants.

Stock Based Compensation (Det39

Stock Based Compensation (Details 2) - Employee Stock Option [Member] - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Outstanding at Beginning	5,353	3,160
Number of Options, Granted	1,960	2,413
Number of Options, Exercised	0	0
Number of Options, Forfeited	(217)	(196)
Number of Options, Expired	(193)	(24)
Number of Options, Outstanding at Ending	6,903	5,353	3,160
Weighted average Excercise Price, Outstanding at Beginning (in dollars per share)	$ 1.06	$ 0.94
Weighted average Excercise Price, Granted (in dollars per share)	0.56	1.22
Weighted average Excercise Price, Forfeited (in dollars per share)	0.95	0.94
Weighted average Excercise Price, Expired (in dollars per share)	0.89	0.96
Weighted average Excercise Price, Outstanding at Ending (in dollars per share)	$ 0.93	$ 1.06	$ 0.94
Outstanding at Contractual Term	8 years 4 months 24 days	9 years 1 month 6 days	9 years 8 months 12 days

Stock Based Compensation (Det40

Stock Based Compensation (Details 3) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options exercisable at end of year	3,752	2,460
Weighted average grant date fair value (per share) of options granted during the period	$ 0.65	$ 0.68

Stock Based Compensation (Det41

Stock Based Compensation (Details 4)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility		68.76%
Risk-free interest rate, Minimum	1.34%	1.65%
Risk-free interest rate, Maximum	1.74%	1.93%
Dividend yield	0.00%	0.00%
Expected life	6 years
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility	102.30%
Expected life		5 years 6 months
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility	71.10%
Expected life		4 years 9 months

Stock Based Compensation (Det42

Stock Based Compensation (Details Textual) - USD ($)	May. 08, 2014	Dec. 31, 2015	Dec. 31, 2014	Aug. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance				9,541,706
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum	4.00%
Share-based Compensation Arrangement by Share-based Payment Award Increase of Shares Offering Date	January 1, 2015
Common Stock, Shares, Issued		57,180,148	32,292,650
Share-based Compensation, Total		$ 1,592,367	$ 1,974,153
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value		$ 600,000
Share-based Compensation Arrangement by Share-based Payment Award, Description		granted at prices not less than 100% of the fair value
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share Based Compensation Total Compensation Cost Not Yet Recognized Stock Options Grants		$ 1,900,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term		1 year 3 months 18 days
Board of Directors Chairman [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock, Shares, Issued		278,784	292,650
Share-based Compensation, Total		$ 200,000	$ 200,000
Clinical Milestones [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares			71,750
Share-based Compensation, Total			$ 28,000

COMMMITMENTS (Details)

COMMMITMENTS (Details)	Dec. 31, 2015USD ($)
Future Lease Rental Payment [Line Items]
2,016	$ 184,520
2,017	160,012
2,018	162,948
2,019	165,896
2020 and beyond	252,764
Total future minimum lease payments	$ 926,140

COMMMITMENTS (Details Textual)

COMMMITMENTS (Details Textual) - USD ($)	1 Months Ended			12 Months Ended
	Jan. 31, 2016	Jun. 30, 2014	Nov. 01, 2013	Dec. 31, 2015	Dec. 31, 2014
Commitments and Officer Loans [Line Items]
Increase Decrease In Lease Rental Expense		$ 14,200
Security Deposit				$ 300,000
Lessor Leasing Arrangements, Operating Leases, Term of Contract			7 years
Operating Leases, Rent Expense, Net, Total		$ 12,723		$ 211,500	$ 95,000
Security Deposits Reduced By Straight Line Basis Description				This deposit was reduced by $100,000 in 2015 and can be reduced by $ 100,000 on an annual basis going forward, down to $50,000, as long as the Company makes timely rental payments.
Revenue Recognition, Milestone Fee On Achieving Sales Threshold				$ 100,000
Minimum [Member]
Commitments and Officer Loans [Line Items]
License Costs				10,000
Maximum [Member]
Commitments and Officer Loans [Line Items]
License Costs				$ 50,000
Subsequent Event [Member]
Commitments and Officer Loans [Line Items]
Operating Leases, Rent Expense, Net, Total	$ 2,287

Income Taxes (Details)

Income Taxes (Details)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Percent of pre-tax income:
U.S. federal statutory income tax rate	34.00%	34.00%
State taxes, net of federal benefit	0.00%	0.10%
Permanent items	(5.30%)	(3.10%)
Research and development credit	3.00%	0.90%
Change in valuation allowance	(31.70%)	(31.90%)
Effective income tax rate	0.00%	0.00%

Income Taxes (Details 1)

Income Taxes (Details 1) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Deferred tax assets (liabilities)
Share-based compensation	$ 518,542	$ 489,017
Depreciation and amortization	37,186	73,894
Warrants	43,997	43,997
Accrued liability	118,386	0
Net operating loss carryforwards	7,093,015	4,379,541
Federal research and development credit carryforwards	525,001	241,318
In process research and development	(1,205,141)	0
Deferred income tax assets	7,130,986	5,227,767
Valuation allowance	(8,336,127)	(5,227,767)
Net deferred tax liabilities	$ (1,205,141)	$ 0

Income Taxes (Details Textual)

Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Taxes [Line Items]
Deferred Tax Assets, Valuation Allowance	$ 8,336,127	$ 5,227,767
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	3,100,000
Operating Loss Carryforwards	19,200,000
New Jersey Division of Taxation [Member]
Income Taxes [Line Items]
State and Local Income Tax Expense (Benefit), Continuing Operations, Total	760,000
Research Tax Credit Carryforward [Member]
Income Taxes [Line Items]
Tax Credit Carryforward, Amount	$ 525,000